Projecting future drug expenditures--2006.

PURPOSE Drug expenditure trends in 2004 and 2005, projected drug expenditures for 2006, and factors likely to influence drug costs are discussed. SUMMARY Various factors are likely to affect drug costs, including drug prices, drugs in development, and generic drugs. In 2004 there was a continued moderation of the increase in drug expenditures. Drug expenditures increased by 8.7% from 2003 to 2004. Through the first nine months of 2005, expenditures increased by only 8.1% compared with 2004. This moderation can be attributed to several factors, including the continued trend toward higher prescription drug cost sharing for insured consumers, growing availability of generic drugs, and lack of "blockbuster" new drugs in recent years. Drug expenditures in 2006 will likely be influenced by similar factors, with few costly new products reaching the market, increased concern over product safety slowing the diffusion of those new agents that do reach the market, and several important patent expirations, leading to slower growth in expenditures. CONCLUSION Forecasting and managing rising drug expenditures remains a challenge. Pharmacy managers must remain vigilant in monitoring drug costs in their health system and take a proactive role in pursuing efficient drug utilization. The dynamic health policy environment further complicates drug budgeting and must be considered, especially in integrated health systems responsible for managing inpatient, outpatient, and clinic drug costs. The comparison of health-system-specific data and trends with the national information presented in this article may provide a useful context when presenting institutional drug costs to senior management.

[1]  Bradley C Strunk,et al.  Tracking health care costs: declining growth trend pauses in 2004. , 2005, Health affairs.

[2]  I. Melnikova Future of COX2 inhibitors , 2005, Nature Reviews Drug Discovery.

[3]  M. Sipkoff Biogenerics at the gate waiting for the FDA to act , 2005 .

[4]  P. Ubel,et al.  Responding to the Immunoglobulin Shortage: A Case Study , 2002, Journal of health politics, policy and law.

[5]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[6]  E. Topol Nesiritide - not verified. , 2005, The New England journal of medicine.

[7]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[8]  The outlook for hospital spending. , 2003, Health affairs.

[9]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[10]  Kathryn A Phillips,et al.  Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 19972000 , 2005, Annals of Internal Medicine.

[11]  H. Büller,et al.  Direct thrombin inhibitors. , 2005, The New England journal of medicine.

[12]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[13]  "Me-too" products--friend or foe? , 2004, The New England journal of medicine.

[14]  S. Keehan,et al.  U.S. health spending projections for 2004-2014. , 2005, Health affairs.

[15]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[16]  P. Gavaza,et al.  Medication counseling in Zimbabwe. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  B. Goldstein,et al.  Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  K. Cantwell,et al.  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: implications for health-system pharmacy. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[20]  M. Sipkoff Generic manufacturers riding a wave of market consolidation , 2005 .

[21]  N. Shah,et al.  Projecting future drug expenditures--2004. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  Nilay D Shah,et al.  Projecting future drug expenditures--2005. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  M. Ratner Neuroimaging heats up , 2005, Nature Reviews Drug Discovery.

[24]  S. Mayer,et al.  Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage , 2007, Stroke.

[25]  R David Yost New economics of the pharmaceutical supply chain. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[26]  B. Wiens,et al.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Hesselgrave Helping to manage the high cost of rare diseases. , 2003, Managed care quarterly.

[28]  Allen R Dunehew Changing dynamics in the pharmaceutical supply chain: a GPO perspective. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[30]  R. Rapp,et al.  Price hikes for generic injectable antibiotics. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[31]  S. Okie What ails the FDA? , 2005, The New England journal of medicine.